Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women | Zendy

Nananda F. Col | Zendy; Stephen G. Pauker | Zendy; Robert J. Goldberg | Zendy; Mark H. Eckman | Zendy; Richard K. Orr | Zendy; Elizabeth M. Ross | Zendy; John B. Wong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women

Author(s) -

Nananda F. Col,

Stephen G. Pauker,

Robert J. Goldberg,

Mark H. Eckman,

Richard K. Orr,

Elizabeth M. Ross,

John B. Wong

Publication year - 1999

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.159.13.1458

Subject(s) - raloxifene , medicine , hormone replacement therapy (female to male) , breast cancer , osteoporosis , selective estrogen receptor modulator , tibolone , tamoxifen , oncology , hormone therapy , menopause , hip fracture , alendronic acid , gynecology , cancer , bisphosphonate , testosterone (patch)

Alendronate sodium and raloxifene hydrochloride were recently approved for the prevention of postmenopausal osteoporosis, but data on their clinical efficacy are limited. We compared these drugs with hormone replacement therapy (HRT) to help women and physicians guide postmenopausal treatment decisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research